EyeMac Regen treatment go Beyond Injections . . .

The Problem

AMD is the leading cause of permanent vision loss. Highly effective treatments exist — particularly intravitreal injections that help millions. However, when macular disease advances despite injections, there are no current treatment options.

Our Origin

EyeMac Regen was not created overnight. It is the result of more than 25 years of careful, methodical, research and engineering design work in a pre-clinical VR surgical environment. Our approach has initiated a discipline that we refer to as incisional choroidal surgery — ICS. Key principles are published in the Lead Article as a Major Review in the Aug-Sept ‘25 Survey of Ophthalmology (Mano et al.). Herein, we establish key foundational surgical principles of this emerging field. This work was developed, tested, and refined across three major academic medical centers with support from donors, the NIH/NEI and leading institutions in ophthalmology.

What We Do

We incorporate mechanical engineering design into ICS techniques that improve surgical efficiency, reliability, and outcomes through data-driven science. Every tool that we design and build is centered on three principles: 1) precision, 2) minimal invasiveness, and 3) uncompromising quality — the standards that VR surgeons require and that patients deserve. EyeMac Regen’s core technology is a permanently implantable scaffold— Macular O-Rings (MORs)—that supports regenerative tissue in the submacular space.

Research

The scientific foundation has been decades in the making and the work continues for the patients who need it most. EyeMac Regen wishes to thank past and continued efforts by Kathy Wabner and Jenn Schmit RN for their long-standing contributions (>25 years each). Also, meaningful research contributions have originated from Stephen LoBue MD, Prashant Tailor MD along with Fukutaro Mano MD, and Norihiro Yamada MD. We thank each of these passionate individuals for their outstanding dedication to our research.

Our Founder

Timothy W. Olsen MD serves as the Chief Executive Officer. Previously, he was Professor & Consultant at Mayo Clinic (2017-23), Rochester Minnesota. From 2007-2016 he served as Chair of Ophthalmology, F. Phinizy Calhoun Sr. Professor, Director of the Emory Eye Center; Emory University in Atlanta, Georgia where he is currently Chair Emeritus (2016-present).